sar425899 glp-1 glucagon dual agonist sanofi Media Centre-mvanhaasteren.nl Focus on Glucagon-like Peptide-1 Target:

Summary Retatrutide, a triple agonist now in phase 3 trials, has the potential to become the most effective pharmacological treatment for obesity while also offering substantial benefits in T2D management and other cardiometabolic risk factors.

To further note, in the field of weight-loss treatment, significant work is underway in parallel, on GIP agonist, amylin agonist, glucagon agonist, PYY agonist, either separately or in combination especially with GLP-1 agonist.

These drugs mimic the effects of the naturally occurring GLP-1 hormone, which is produced in the small intestine and plays a crucial role in regulating insulin secretion, glucose homeostasis, and appetite.

As online weight-loss clinics boom, reports of GLP-1 overdoses, dosing mistakes, and hospitalizations are climbing.

While most of the recent fanfare has been related to their ro...